Tevogen Bio expects to eliminate $94.9M liabilities via note conversion; launches AI initiative, appoints new leaders

Tevogen Bio Holdings Inc.

Expects to report $94.9M liability elimination from conversion of promissory notes into common stock.
Pro forma balance sheet shows no remaining convertible note liabilities; $80.7M current and $14.2M long-term removed.
Operating expenses for Tevogen Bio Inc. in 2023 were $8.8M, primarily non-cash charges from note fair value changes.
Launches Tevogen.ai AI initiative to enhance drug discovery, manufacturing, and patient access; Mittul Mehta appointed CIO.
Appoints Tapan V. Shah as Head of Investor Relations and Corporate Development; 25-year Wall Street veteran.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Tevogen Bio Holdings Inc. reported preliminary financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: preliminary results

Exact text from the filing

On April 26, 2024, Tevogen Bio Holdings Inc. (the “Company”) issued a press release announcing certain expected pro forma combined financial results of the Company and the Company’s wholly owned subsidiary, Tevogen Bio Inc. (“Tevogen Bio”), and certain expected financial results of Tevogen Bio as of and for the year ended December 31, 2023.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Tevogen Bio Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-016060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.